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Introduction: Rotavirus vaccination with the live-
attenuated monovalent (a G1P[8] human rotavirus 
strain) two-dose Rotarix vaccine was introduced in 
England in July 2013. Since then, there have been 
significant reductions in rotavirus gastroenteritis 
incidence. Aim: We assessed the vaccine’s impact on 
rotavirus genotype distribution and diversity 3 years 
post-vaccine introduction. Methods: Epidemiological 
and microbiological data on genotyped rotavirus-pos-
itive samples between September 2006 and August 
2016 were supplied by EuroRotaNet and Public Health 
England. Multinomial multivariable logistic regression 
adjusting for year, season and age was used to quan-
tify changes in genotype prevalence in the vaccine 
period. Genotype diversity was measured using the 
Shannon’s index (H’) and Simpson’s index of diversity 
(D). Results: We analysed genotypes from 8,044 faecal 
samples. In the pre-vaccine era, G1P[8] was most prev-
alent, ranging from 39% (411/1,057) to 74% (527/709) 
per year. In the vaccine era, G1P[8] prevalence 
declined each season (35%, 231/654; 12%, 154/1,257; 
5%, 34/726) and genotype diversity increased sig-
nificantly in 6–59 months old children (H’ p < 0.001: 
D p < 0.001). In multinomial analysis, G2P[4] (adjusted 
multinomial odds ratio (aMOR): 9.51; 95% confidence 
interval (CI): 7.02–12.90), G3P[8] (aMOR: 2.83; 95% CI: 
2.17–3.81), G12P[8] (aMOR: 2.46; 95% CI: 1.62–3.73) 
and G4P[8] (aMOR: 1.42; 95% CI: 1.02–1.96) signifi-
cantly increased relative to G1P[8]. Conclusions: In the 
context of reduced rotavirus disease incidence, geno-
type diversity has increased, with a relative change 
in the dominant genotype from G1P[8] to G2P[4] after 
vaccine introduction. These changes will need contin-
ued surveillance as the number and age of vaccinated 
birth cohorts increase in the future.
Introduction
Prior to the introduction of rotavirus vaccination, Group 
A rotaviruses were the most common cause of severe 
childhood diarrhoea globally, resulting in over 450,000 
deaths in children aged under 5 years [1]. In England 
and Wales, rotavirus accounted for ca 80,000 general 
practice (GP) consultations and was responsible for 
45% of acute gastroenteritis hospital admissions [2,3]. 
In July 2013, the United Kingdom (UK) introduced the 
monovalent (G1P[8]) live-attenuated, two-dose oral 
human vaccine (Rotarix, GlaxoSmithKline Biologicals, 
Rixensart, Belgium) into the routine childhood immuni-
sation schedule at 8 and 12 weeks of age [4]. Rotavirus 
vaccine uptake increased rapidly to over 90% for one 
dose and has remained consistently high; in July 2016, 
vaccine uptake was over 94% for one dose and over 
90% for the recommended two-dose schedule [5]. In 
high-income countries, efficacy of the monovalent 
G1P[8] Rotarix vaccine against severe rotavirus gas-
troenteritis was estimated at over 85% and further tri-
als have shown that it is efficacious against multiple 
rotavirus strains [6,7]. Since vaccine implementation in 
the UK, data from laboratory reports, hospital admis-
sions and GP consultations have shown a significant 
reduction in the incidence of rotavirus gastroenteritis 
in vaccine eligible children (children born since 01 May 
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2013), older vaccine ineligible children and adults (≥ 18 
years) [8-11].
Group A rotaviruses are defined by the middle cap-
sid antigen and further classified into G and P types 
based on serological and genetic characterisation of 
two outer viral proteins, the VP7 (a glycoprotein) and 
the VP4 (a protease sensitive protein), respectively. 
Furthermore, whole genome sequencing has allowed 
rotavirus strains to be classified according to genotype 
constellations by using a common genetic backbone 
constellation (defined by nine of eleven gene seg-
ments, excluding VP7 and VP4). Among human group A 
rotaviruses there are two common genotype constella-
tions: Wa-like and DS-1 like [12].
Prior to introduction of rotavirus vaccination, genotype 
G1P[8] was the predominant circulating rotavirus geno-
type in the UK [13-17]. In England, like in most countries 
that have recently introduced rotavirus vaccination, 
monitoring the impact of the rotavirus vaccine includes 
the assessment of changes in healthcare utilisation 
and disease incidence, as well as monitoring geno-
type distribution. Rotavirus genotype surveillance has 
been undertaken systematically pre- and post-vaccine 
introduction in the context of the European Rotavirus 
Network, EuroRotaNet, which was established in 
January 2007 and has 14 member countries, including 
the UK [18,19]. Each member country conducts rotavirus 
genotype surveillance; laboratory and epidemiological 
data are also collated within the network to generate 
comprehensive information on the rotavirus genotypes 
co-circulating throughout Europe. This multi-centre 
and data-sharing network approach allows widespread 
monitoring of circulating rotavirus genotypes in order 
to identify: (i) possible vaccine-induced emergence of 
antibody escape mutants; (ii) possible emergence of 
non-vaccine genotypes; and (iii) possible emergence 
of reassortants between vaccine-type and naturally cir-
culating wild-type strains.
Because England has one of the largest historical rota-
virus genotype databases in Europe, dating back to the 
late 1990s [13,16,17], and has used consistent labora-
tory diagnostics and genotyping methods, it is an ideal 
study location for monitoring any changes in geno-
type distribution post-vaccine introduction. This study 
evaluates the impact of routine childhood rotavirus 
vaccination on relative changes in rotavirus genotype 
distribution and diversity in England.
Methods
Study area and samples
The study area was England, covering all regions. Public 
Health England (PHE), Colindale, receives electronic 
laboratory reports of laboratory-confirmed rotavirus 
infections from diagnostic laboratories in England and 
Wales. In this study, samples included rotavirus-posi-
tive faecal samples from mostly sporadic gastroenteri-
tis cases (if associated with outbreaks, only a single 
sample per outbreak) submitted for routine diagnos-
tic testing and genotyped at the PHE Virus Reference 
Department (VRD) using standardised G and P typing 
methods [14,20].
Prior to vaccine introduction, selection of rotavirus-
positive samples for genotyping was passive. As part 
of EuroRotaNet, regional laboratories in England sub-
mitted any rotavirus-positive residual samples to the 
VRD. Although submission of samples to VRD was not 
actively followed-up, at a country level the minimum 
target number of specimens included for genotyping 
would enable detection of rotavirus genotypes with a 
prevalence of ≥ 1% [19].
When the infant rotavirus vaccination programme was 
introduced in July 2013, the Immunisation Department 
at PHE initiated active surveillance for rotavirus. 
Hospital laboratories across England and Wales were 
actively requested to submit all rotavirus-positive sam-
ples in vaccine-eligible children to the PHE VRD for 
confirmation and genotyping. After the introduction 
of rotavirus vaccination G1P[8] vaccine-derived strains 
were defined on the basis of the sequences of the VP4 
and VP7 encoding genes displaying highest homology 
with Rotarix sequences and/or through the detection of 
the Rotarix strain using a published and validated qRT-
PCR assay which specifically targets the non-structural 
protein 2 (NSP2) gene of the Rotarix strain [21].
Data
The sampling methods used mean that the data in this 
study do not represent rotavirus incidence but allow us 
to assess relative changes in genotype distributions. 
Details on case age, region, specimen collection date 
and rotavirus genotyping results for specimens col-
lected between September 2006 and August 2016, 
were included in this study. Data on cases’ sex were 
incomplete, so we were unable to include these in the 
analyses however, previous analysis of EuroRotaNet 
data has shown that there is no difference in genotype 
distribution by sex [19].
While EuroRotaNet was established in January 2007, 
data dating back to September 2006 were retro-
spectively collected by this network. Thus data 
from September 2006 to December 2012 are held by 
EuroRotaNet and, and from January 2013 to August 
2016, jointly by EuroRotaNet and PHE. In order to main-
tain complete surveillance years (September to August) 
for analysis, the pre-vaccine period was defined as 
September 2006 to August 2013 and the vaccine period 
was defined as September 2013 to August 2016.
Age groups of cases (< 6 months, 6–11 months, 12–23 
months, 2–4 years and ≥  5 years) were constructed 
using date of birth and date of specimen submis-
sion. Genotyped rotavirus strains were categorised 
according to their possible evolutionary origin [14]. A 
derived binary ‘season’ variable was constructed to 
indicate whether a rotavirus case occurred during the 
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pre-vaccine introduction peak rotavirus season (cal-
endar week 1 to week 25) or the non-peak rotavirus 
season (calendar week 26 to week 52) according to the 
date of specimen collection [17].
For the purposes of statistical analyses (apart from 
genotype diversity), because of the large number of 
genotypes, any single genotype which contributed < 1% 
of samples over the study period was classified into a 
generic ‘other’ category for ‘rarer’ genotypes. A sepa-
rate grouping ‘mixed or untypable’ was established for 
any mixed (more than one genotype found in one indi-
vidual sample) or partially typed strains.
Vaccination status
As part of the enhanced surveillance, the general prac-
titioner of each rotavirus-positive infant in the vac-
cine-eligible age group (born since 01 May 2013) was 
contacted to establish their rotavirus vaccine history. 
For this study, the vaccine history was assessed for 
samples with a G1P[8] vaccine-derived strain. The vac-
cination history, included number of rotavirus vaccine 
doses received and date of vaccination.
Data analysis
Descriptive analysis
Data analyses were performed using R version 3.3.2 
[22]. The distribution of rotavirus G- and P-genotypes 
was tabulated in respect to age group, year, and period 
(pre- or post-vaccine introduction). Differences between 
continuous variables were tested using Student’s t-test 
or Wilcoxon rank-sum test if not normally distributed 
and chi-squared-test or Fisher’s exact test for cate-
gorical variables. Any G1P[8] vaccine-derived samples 
were excluded from the statistical analyses under the 
assumption that they were not the disease causative 
agent.
Genotype differences pre- and post-vaccine introduction
To investigate relative statistical differences in circulat-
ing genotypes pre- and post-vaccine introduction, we 
fitted multinomial logistic regression models, with gen-
otype as the outcome and G1P[8] as the baseline geno-
type. Model fitting was based on season, surveillance 
year and age group; these terms were identified a pri-
ori [17]. The model was first run as a univariable analy-
sis including only the binary vaccine period variable 
Table
Number of rotavirus specimens collected in the pre-vaccine era and the vaccine era, by genotype and age group, England, 
September 2006–August 2016 (n = 8,044)
Characteristic
Pre-vaccine era Vaccine era
Sep 2006–Aug 2013 
 
(n = 5,407)
Sep 2013–Aug 2014 
 
(n = 654)
Sep 2014–Aug 
2015 
 
(n = 1,257)
Sep 2015–Aug 2016 
 
(n = 726)
Sep 2013–Aug 
2016 
 
(n = 2,637)
Genotype n % n % n % n % n %
G1P[8] 2,987 55 231 35 154 12 34 5 419 16
G2P[4] 397 7 28 4 345 27 325 45 698 26
G3P[8] 527 10 190 29 101 8 61 8 352 14
G4P[8] 368 7 53 8 103 8 21 3 177 7
G8P[4] 118 2 0 0 0 0 2 0 2 0
G9P[8] 597 11 46 7 191 15 134 18 371 14
G12P[8] 122 2 19 3 242 19 17 2 278 11
G1P[8]-unknowna 0 0 0 0 0 0 3 0 3 0
G1P[8]-VD 0 0 64 10 84 7 67 9 215 8
Otherb 91 2 6 1 27 2 32 4 65 2
Mixedc and untypable 200 4 17 3 10 1 30 4 57 2
Age groupd n % n % n % n % n %
 < 6 months 577 11 169 25 233 19 102 15 504 20
6–11 months 1,194 24 105 16 124 9 61 9 290 11
12–23 months 1,851 37 261 40 407 34 234 34 902 35
2–4 years 940 19 81 12 369 34 238 35 688 27
 ≥ 5 years 464 9 37 6 79 7 52 8 168 7
VD: vaccine-derived.
a G1P[8]-unknown: unknown whether these strains are wild-type G1P[8] or VD.
b ‘Other’ refers to rarer genotypes, which contributed < 1% of samples over the study period.
c Mixed: more than one genotype found in an individual sample.
d There were 466 specimens with unknown case age. Percentages are calculated from total specimens with known case age.
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for before or after vaccine introduction. Age-stratified 
models were also run; with genotype as the outcome 
variable, and vaccine period, season and surveillance 
year as covariates. Multinomial odds ratios (MOR), 
95% confidence intervals (CI) and the associated p val-
ues were calculated from the Wald test. Results were 
considered significant at p < 0.05.
Rotavirus genotype diversity was compared using 
two established biodiversity indices, Simpson’s index 
of diversity (D) and Shannon’s index (H) [23]. All sin-
gle typed rotavirus genotypes were included in the 
analysis. Simpson’s index of diversity (D) has a range 
between 0 and 1 (maximum diversity) and represents 
the probability that two randomly chosen rotavirus 
genotypes will have different G and P types and is 
calculated as 1  −  λ, where λ = Σ(pi2) and pi is the pro-
portional abundance of a genotype i. Shannon’s index 
(H’) ranges from 0 (no diversity) to Y (maximum) and 
quantifies the uncertainty in predicting the rotavirus 
genotype identity of an individual sample that is taken 
at random from the dataset and is calculated as H’ 
=   − Σ(pi  x  ln(pi)) [17]. Confidence intervals were esti-
mated using bootstrap resampling methodology and 
differences by age group, pre- and post-vaccine intro-
duction were compared using p values generated from 
z-scores during bootstrap analysis. The R packages 
‘vegan’ and ‘boot’ were used for the analysis of geno-
type biodiversity [24,25].
Results
Descriptive statistics
In England a total of 8,044 rotavirus-positive speci-
mens were genotyped between September 2006 and 
August 2016. Six per cent of specimens (n = 466) had 
no detail on case age, and most of these were from 
2007/08 (n = 209/737; 28%) and 2011/12 (n = 137/732; 
19%). The case age ranged from <1 month to 104 years 
and the majority of specimens were from children 
aged < 5 years (92%; 6,945/7,578), with most speci-
mens (56%; 4,237/7,578) from children aged 6–23 
months (Table). Prior to vaccine introduction, the rota-
virus season consistently occurred between January 
and May, with the peak occurring during March. After 
the introduction of rotavirus vaccination, the seasons 
became less pronounced; in the first surveillance year 
post-vaccine introduction (2013/14), the peak occurred 
in March, but in 2014/15 and 2016/17 the peak was in 
May and season lasted longer into July (Figure 1).
Genotype distribution
In the pre-vaccine period (September 2006 to August 
2013), G1P[8] was the overall predominant genotype 
(55%), ranging from 39% (411/1,057) to 74% (527/709) 
per year (Table). In cases aged 5 years and older, G1P[8] 
was less dominant than in younger age groups, repre-
senting 34% (156/464) of all specimens genotyped, 
while genotypes G2P[4] (16%; 73/464) and G8P[4] (8%; 
39/464) were more prevalent (Figure 2).
In the first surveillance year of the vaccine era (2013/14), 
G1P[8]-type viruses appeared to become less dominant 
overall, accounting for 35% of genotyped samples; in 
the same period, G3P[8] accounted for 29% (Table). In 
surveillance years two (2014/15) and three (2015/16) of 
the vaccine era, G2P[4]-type viruses accounted for the 
highest proportion of strains (27% and 45%, respec-
tively). In these two surveillance years wild-type G1P[8] 
viruses seemed to become less prevalent, accounting 
for 12% of genotyped specimens in 2014/15 and 5% in 
2015/16. Also, in 2014/15, G12P[8]-type viruses repre-
sented 19% of samples, compared with 2% in the pre-
vaccine period.
In the pre-vaccine period G1P[8] was dominant in all 
children under 5 years of age (Figure 2). In the vac-
cine period, the distribution of rotavirus genotypes 
in infants younger than 6 months of age was differ-
ent to the other age groups; wild-type G1P[8] viruses 
were present in 28% (141/504) of cases and vaccine-
derived G1P[8] strains were detected in 38% (193/504) 
of cases (Figure2). G1P[8] was detected less frequently 
as age increased, it was detected in 18% (51/290) of 
6–11 month olds, 14% (126/902) of 12–23 month olds, 
11% (78/688) of 2–4 year olds, and 9% (15/168) of ≥ 5 
year-olds. The change in strain distribution between 
the pre-vaccine and vaccine era for all ages was sig-
nificant when excluding vaccine-derived G1P[8] strains 
(chi-squared = 1,509, degrees of freedom = 8; p < 0.001).
Figure 1
Number of rotavirus specimens typed per month and 
surveillance year, England, September 2006–August 2016 
(n = 8,044)
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Vaccine-derived strains
After rotavirus vaccine introduction in the UK in July 
2013 there were 215 G1P[8] vaccine-derived strains 
detected.
Of the 208 with an age recorded, 92% (n = 191/208) 
were detected in infants aged 2–5 months of age, who 
would have been eligible for immunisation. Among 
these cases, six were unvaccinated infants, vaccine 
status was unknown for three and five were vacci-
nated after the sample collection date. The remaining 
(n = 177) were vaccinated with a median time between 
specimen date and most recent rotavirus vaccine dose 
of 13 days (interquartile range (IQR): 7–23) and a maxi-
mum of 154 days.
There were 12 instances where vaccine-derived G1P[8] 
strains were found in specimens from children eligible 
for vaccination but older than 6 months of age when 
the sample was taken. Of these, one sample had come 
from an unvaccinated patient and one from a non-UK 
resident; the remaining 10 were from patients who 
had received at least one dose of rotavirus vaccine 
between 83 days and 420 days before the sample col-
lection date.
Figure 2
Genotype proportions of typed rotavirus specimens by surveillance year and age group, England, September 2006–August 
2016 (n = 8,044)
n=90 n=70 n=111 n=72 n=71 n=51 n=112 n=169 n=233 n=102
n=150 n=110 n=146 n=128 n=101 n=135 n=170 n=81 n=369 n=238
n=204 n=100 n=174 n=175 n=122 n=120 n=299 n=105 n=124 n=61
n=45 n=33 n=86 n=74 n=85 n=36 n=105 n=37 n=79 n=52
n=290 n=215 n=288 n=251 n=184 n=253 n=370 n=261 n=407 n=234
n=793 n=737 n=813 n=709 n=566 n=732n=1057 n=654n=1257 n=726
2−4 years ≥ 5 years All ages
<6 monthsAge 6−11 months 12−23 months
06
/0
7
07
/0
8
08
/0
9
09
/1
0
10
/1
1
11
/1
2
12
/1
3
13
/1
4
14
/1
5
15
/1
6
06
/0
7
07
/0
8
08
/0
9
09
/1
0
10
/1
1
11
/1
2
12
/1
3
13
/1
4
14
/1
5
15
/1
6
06
/0
7
07
/0
8
08
/0
9
09
/1
0
10
/1
1
11
/1
2
12
/1
3
13
/1
4
14
/1
5
15
/1
6
0
20
40
60
80
100
0
20
40
60
80
100
Surveillance year
Pr
op
or
tio
n 
of
 s
pe
ci
m
en
s 
(%
)
G1P[8] G2P[4] G4P[8] G8P[4] G9P[8]
G12P[8] G1P[8]−UK−unknowna G1P[8]−VD Otherb Mixedc and untypable
G3P[8]
Age Age
UK: United Kingdom; VD: vaccine derived.
a G1P[8]-unknown: unknown whether these strains are wild-type G1P[8] or VD.
b ‘Other’ refers to rarer genotypes which contributed < 1% of samples over the study period.
c Mixed: more than one genotype found in an individual sample.
There were 466 specimens with unknown case age. Percentages are calculated from total specimens with known case age. The genotyping 
analyses’ results are indicated by different colours, as explained in the legend.
6 www.eurosurveillance.org
A further two cases were aged < 2 months of age; one 
had received the first dose of rotavirus vaccine 5 days 
before the date of sample collection and the other 
case had not received any vaccine doses at the time 
of sampling.
Three cases, aged 23 months, 3 years and 4 years were 
born before vaccine introduction and therefore, would 
have been too old for the UK rotavirus immunisation 
programme. Vaccine status for a 23 month-old and 4 
year-old could not be followed-up, but the 3 year-old 
had received the second dose of the rotavirus vaccine 
2 days before the date of the sample.
Age
In the pre-vaccine period, the majority of samples 
referred were from children aged 6–23 months (61%; 
3,045/5,026). In the vaccine era, when excluding 
G1P[8] vaccine-derived cases, most samples were from 
children aged 12–59 months (68%; 1,584/2,344). In the 
pre-vaccine era, the median age was 13 months (IQR: 
9–24) compared with 19 months (IQR: 11–29) in the 
vaccine period (W = 572,300; p < 0.001).
Multinomial logistic regression
Although G8P[4] was detected in more than 1% of 
samples across the study period, for the multinomial 
regression analyses, G8P[4] was classified as a rare 
genotype because it was only detected in 2008/09 
(n = 45); 2009/10 (n = 73) and 2015/16 (n = 2). We also 
excluded G1P[8] vaccine-derived strains from the 
models, under the assumption that the majority were 
detected in vaccinated infants and were, therefore, not 
the causative agent of the gastroenteritis symptoms. 
When adjusting for surveillance year, season and age 
group, the adjusted multinomial odds ratios (aMOR) 
of infection caused by the following genotypes: G2P[4] 
(aMOR: 9.51; 95% CI: 7.02–12.90; p < 0.001); G3P[8] 
(aMOR: 2.83; 95% CI: 2.17–3.81; p < 0.001); G12P[8] 
(aMOR: 2.46; 95% CI: 1.62–3.73; p < 0.001); mixed and 
untypable (aMOR: 2.00; 95% CI: 1.20–3.36; p < 0.01); 
and other rarer (aMOR: 2.6; 95% CI: 1.63–4.17; p < 0.001); 
G4P[8] (aMOR: 1.42; 95% CI: 1.02–1.96; p = 0.03), were 
higher in the vaccine era relative to wild-type G1P[8], 
while cases due to G9P[8] (aMOR: 1.06; 95% CI: 0.81–
1.38; p = 0.661) were unchanged (Figure 3; full model). 
In age-stratified analysis, across all age groups G2P[4] 
became significantly more prevalent in the vaccine 
era relative to wild-type G1P[8] (Figure 3). In infants 
younger than 6 months of age, G2P[4] (aMOR: 3.04; 
95% CI: 1.18–7.88; p = 0.02) was the only genotype 
that was significantly more prevalent in the vaccine era 
relative to wild-type G1P[8].
Genotype diversity
There were 30 different single rotavirus genotypes 
(G10P[4], G12P[10], G12P[4], G12P[6], G12P[8], G1P[4], 
G1P[5], G1P[6], G1P[8], G2P[10], G2P[4], G2P[6], G2P[8], 
G2P[9], G3P[14], G3P[3], G3P[4], G3P[6], G3P[8], G3P[9], 
G4P[4], G4P[8], G6P[14], G6P[9], G8P[14], G8P[4], 
G8P[8], G9P[4], G9P[6], G9P[8]) identified between 
September 2006 and August 2016. Genotype diversity 
increased significantly in the vaccine era compared 
with the pre-vaccine era (Figure 4), and variation across 
the age groups was observed. There were significant 
increases in the genotype diversity among infants 
aged 6–11 months (H’: p < 0.001; D: p < 0.001); children 
aged 12–23 months (H’: p < 0.001; D: p < 0.001) and chil-
dren 24–59 months of age (H’: p < 0.001; D: p < 0.001). 
However, there was no change in genotype diversity 
among cases aged 5 years and older (H’: p = 0.477; D: 
p = 0.471). An increase in genotype diversity was only 
observed in infants < 6 months of age when using the 
Simpsons index (D: p = 0.024).
In the pre-vaccine era, genotype diversity was signifi-
cantly higher in individuals aged 5 years and older than 
in any other age group but this is no longer true after 
rotavirus vaccine introduction, genotype diversity was 
comparable across those aged 6–11 months; 12–23 
months, 24–59 months and those aged 5 years and 
older. Furthermore, genotype diversity in all of these 
groups was significantly higher than that in infants 
aged less than 6 months (for all comparison ages, H’: 
p<0.001 and D’: p<0.001).
Discussion
There has been a change in rotavirus genotype distribu-
tion and diversity in England following the introduction 
of rotavirus vaccination for all infants in 2013. In the 
context of very high rotavirus vaccine uptake (ca 94%) 
[5], there has been both an increase in the genotype 
diversity among symptomatic cases and a change in 
the dominant circulating genotype from G1P[8] in the 
pre-vaccine era to G2P[4] in the vaccine era.
G2P[4] genotypes have been associated with out-
breaks in older children (11–12 years) and adults in the 
absence of rotavirus vaccination or shortly after the 
introduction of rotavirus vaccination programmes [26-
29]. The higher proportion of G2P[4] cases in the vac-
cine-era has coincided with an increase in the median 
age of cases, and a decline in cases among vaccine 
age-eligible age groups. These data may be interpreted 
in the context of varying strain fitness and partial hete-
rotypic protection. Rotavirus G2P[4] genotypes may be 
displaced by other, better adapted or fitter genotypes 
such as G1P[8], particularly in an immunologically naive 
population. The association of G2P[4] with more fre-
quent infection in older unvaccinated individuals who 
are likely to have had previous rotavirus infections sug-
gests that the level of cross-protection against G2P[4] 
is not the same as that against the other genotype con-
stellation 1 (Wa-like) strains (typically G1P[8], G3P[8], 
G4P[8], G9P[8] and G12P[8]) [29].
In the vaccine era, the higher proportion of wild-
type G1P[8] in infants < 6 months of age compared 
with older age groups could potentially indicate that 
wild-type G1P[8] remains the most competitive strain 
when infecting immunologically naive populations. In 
the absence of a vaccine programme the competitive 
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advantage of G1P[8] strains appears to wane as infants 
become older and are exposed to repeated infections 
conferring protection through a varying degree of het-
erotypic immunity. The introduction of the monovalent 
rotavirus vaccine provides universal exposure to G1P[8] 
rotavirus among infants, with protection that is likely 
to be higher against homotypic strains than hetero-
typic ones, such as G2P[4], meaning that natural infec-
tion leading to disease is more likely to be caused by 
such heterotypic strains. This is further evidenced by 
the increase in rotavirus genotype diversity in samples 
from children aged 6 to 59 months.
The dominance of wild-type G1P[8] in the pre-vaccine 
period is also consistent with independent stud-
ies conducted in England during the late 1990s and 
early 2000s [13,15,16]. This adds strength to the evi-
dence from this study that the decline in the relative 
proportion of wild-type G1P[8] and the relative rise of 
heterotypic strains such as G2P[4] in the vaccine-era is 
related to vaccine introduction rather than concurrent 
natural fluctuation. Furthermore, countries such as 
Belgium, Germany and Scotland introduced the Rotarix 
vaccine into their national childhood vaccination 
schedules in 2006, 2013 and 2013, respectively, and 
have all since seen an absolute decline in G1P[8], with 
a rise in the proportion and absolute number of G2P[4] 
strain detections; Belgium reported slightly lower 
vaccine effectiveness against G2P[4] and Germany 
detected proportionally more G2P[4] genotypes in 
Rotarix-vaccinated children [30-33]. This is also true 
in lower income countries such as Malawi where point 
estimates for Rotarix vaccine effectiveness were lower 
against G2 strains than G1 strains (53% vs 82%) [34].
Figure 3
Age-stratified crude and adjusted multinomial odds ratios for genotypes occurring before and after rotavirus vaccine 
introduction, England, September 2006–August 2016 (full model; n = 7,368)
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symptoms. P values for adjusted multinomial odds ratios * p < 0.05, ** p < 0.01, ***p < 0.001.
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The relative rise of G12P[8] in 2014/15 across all age 
groups is likely to reflect natural seasonal fluctua-
tions and global emergence rather than a force of vac-
cine selection. Belgium also experienced an increase 
in rotavirus cases with G12P[8] detection in 2014/15 
[35]. Rapid increases and subsequent declines of 
G12P[8] have been seen in other European countries; in 
2011/12, G12P[8] was the dominant strain in Spain; with 
the majority of detections occurring in the Gipuzkoa 
region of north eastern Spain; however, detections of 
G12P[8] fell in 2012/13 [36]. There has also been inde-
pendent introduction of G12 strains into Italy in recent 
years [37]. The emergence of G12 strains in countries 
both with and without rotavirus vaccination has been 
reported globally since 2004 [38-40].
In the pre-vaccine era, the predominant genotype 
G1P[8] declined with increasing age, intimating differ-
ences in homotypic and heterotypic immunity gener-
ated by natural infection over a person’s life-course. It 
is, therefore, possible that the concept of ‘antigenic sin’ 
is applicable to rotavirus and vaccination. If this is the 
case, it may be expected that immunity to the homo-
typic strains may be sustained long-term even if cir-
culation of G1P[8] rotaviruses is significantly reduced, 
through reinfections with other genotypes. This com-
bination of factors poses the question as to whether 
vaccination will effectively mimic long-term protection 
previously generated through multiple natural infec-
tions and whether this could, in the future, result in a 
shift to milder disease caused by heterotypic strains in 
older vaccinated children.
In this study, we identified a number of cases with 
G1P[8] vaccine-derived strains. The majority of these 
were detected in vaccinated children aged 2 to 5 
months and are likely not to be the cause of the symp-
toms. These children could be shedding vaccine strain 
after vaccination and illness is perhaps caused by 
other infectious pathogens or non-infectious aetiolo-
gies [41-43]. Furthermore, the high proportion of G1P[8] 
vaccine-derived strains may to some extent be the 
result of the increasing use of molecular methods in 
diagnostic laboratories across England; these methods 
will detect shedding of vaccine strain, potentially for 
months after vaccination, because of higher sensitivity 
compared with antigen detection methods [44,45].
The detection of G1P[8] vaccine-derived strains in 
older vaccine-eligible and vaccine-ineligible children 
would potentially suggest some horizontal transmis-
sion from vaccinated infants or persistent shedding 
in a vaccinated immunosuppressed child, such as 
those with severe combined immune deficiency [46]. 
A randomised placebo-controlled trial study in twins 
showed instances of horizontal transmission of vaccine 
strains between a vaccinated and unvaccinated twins 
but without gastroenteritis symptoms [47]. In the case 
of those G1P[8] vaccine-derived strains detected pre-
vaccine introduction, this could be due to: vaccination 
in another country; privately accessed vaccination; and 
travel to or contact with children from countries where 
vaccination was available.
Strengths and limitations
Our analysis has benefited from England having one 
of the largest historic rotavirus surveillance systems 
in Europe. These data provide sufficient sample size 
year on year to detect genotypes with a prevalence 
of ≥ 1%, allowing the analyses of the relative genotype 
prevalence and diversity presented. Importantly, this 
allowed us to adjust for seasonal trends and fluctua-
tions in the models. We were also able to establish the 
Figure 4
Rotavirus genotype diversity measured using Shannon’s 
index and Simpson’s index of diversity, with 95% 
confidence intervals, by age group and vaccine period, 
England, September 2006–August 2016 (n = 7,128)
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vaccine status of cases with a detected G1P[8] vaccine-
derived strain.
However, there are limitations which need to be con-
sidered. Principally, it is important to be clear that the 
data included in this study are not representative of 
disease burden or incidence for the following reasons. 
Firstly, patients with acute gastroenteritis are advised 
not to seek medical help, because symptoms are usu-
ally self-limiting, particularly in older children and 
adults. Even if individuals seek medical attention, the 
National Institute of Clinical Excellent (NICE) guidance 
and UK guidance advise that testing for rotavirus is a 
clinical decision, recommended for children under 5 
years of age with symptoms, particularly if symptoms 
are severe, prolonged or atypical [48,49]. Therefore, 
faecal specimens sent by clinicians for laboratory diag-
nostics are more likely to be from patients under 5 
years of age with moderate to severe disease.
Secondly, even after identifying a rotavirus-positive 
sample, genotyping is reliant on the laboratory send-
ing the specimen to the PHE VRD. Since 2013, all 
rotavirus-positive samples from vaccine eligible chil-
dren have been actively followed up by PHE with the 
diagnostic laboratory. But, before vaccine introduction 
in 2013, genotype surveillance of rotavirus-positive 
samples was more passive and laboratory dependent. 
Furthermore, the sample size was calculated to detect 
rotavirus genotypes with a prevalence of ≥ 1% not for 
estimating rotavirus incidence.
Finally, from 2013 onwards, more laboratories were 
using molecular methods for diagnostics. As molecular 
techniques for rotavirus diagnosis are overly sensitive 
and less representative of symptomatic infection com-
pared with antigen detection methods, it is possible 
that a greater proportion of samples were from cases 
where another infectious or non-infectious cause is 
responsible for the gastroenteritis symptoms. It would, 
therefore, be beneficial if samples could be tested for 
other gastrointestinal pathogens, especially in the 
case of G1P[8] vaccine-derived samples.
Conclusions
Rotavirus disease burden in England has greatly 
decreased since the introduction of rotavirus vacci-
nation in 2013. This study shows that rotavirus geno-
type distribution and diversity has also changed in 
England since the introduction of vaccination with a 
large relative shift towards G2P[4], G3P[8] and G12P[8]. 
These changes will need continued surveillance, espe-
cially as the number and age of the vaccinated birth 
cohort’s increase over the coming years. The results 
presented here and continued genotype surveillance 
across Europe through EuroRotaNet will help to inform 
whether future modifications to rotavirus vaccines may 
be needed. Ideally, a prospective birth cohort study 
would be used to assess both disease incidence and 
prevalence of rotavirus genotypes in symptomatic 
infections. Specifically, investigating how homotypic 
and heterotypic protection delivered by the vaccine 
compares to that induced by natural infection and in 
relation to age would be relevant.
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